Celldex Announces Major Underwritten Public Equity Offering

Celldex ( (CLDX) ) has shared an update.

On April 1, 2026, Celldex Therapeutics entered an underwriting agreement with Leerink Partners and TD Securities for an underwritten public offering of 10,345,000 shares of common stock at $29.00 per share, expected to raise about $282 million in net proceeds, with closing anticipated around April 6, 2026. The underwriters also received a 30-day option to purchase up to 1,551,750 additional shares, and the company issued same-day press releases announcing the launch and pricing of the offering, which is intended to support commercial readiness and potential launch of barzolvolimab for chronic spontaneous urticaria, advance its broader antibody pipeline and bispecific platform, and fund general corporate purposes.

The most recent analyst rating on (CLDX) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Celldex stock, see the CLDX Stock Forecast page.

Spark’s Take on CLDX Stock

According to Spark, TipRanks’ AI Analyst, CLDX is a Neutral.

The score is held back primarily by weak and worsening financial performance (deep losses, declining revenue, and accelerating cash burn), partially offset by a very low-debt balance sheet. Technicals are a positive with strong trend and momentum, though overbought signals add near-term risk. Valuation remains constrained by negative earnings and no dividend.

To see Spark’s full report on CLDX stock, click here.

More about Celldex

Celldex Therapeutics, Inc. is a clinical-stage biotechnology company focused on the science of mast cell biology and the development of antibody-based therapeutics. Its pipeline targets severe inflammatory, allergic, autoimmune and other debilitating diseases, aiming to engage the immune system and modulate critical disease pathways.

Average Trading Volume: 871,827

Technical Sentiment Signal: Buy

Current Market Cap: $2.08B

For a thorough assessment of CLDX stock, go to TipRanks’ Stock Analysis page.